Control of arterial hypertension and risk of new-onset of atrial fibrillation in patients with metabolic syndrome

Main Article Content

Ylber Jani*
Kastriot Haxhirexha
Ferizat Haxhirexha
Bekim Pocesta
Atila Rexhepi
Fatmir Ferati
Ahmet Kamberi
Agim Zeqiri
Sotiraq Xhunga
Artur Serani
Lutfi Zylbeari

Abstract

Background: An association between Atrial Fibrillation (AF) and Metabolic Syndrome (MS) a constellation of abnormalities (high blood pressure, hyperglycemia, dyslipidemia, and abdominal obesity), has been demonstrated. There have been many studies that have shown that elevated blood pressure (BP), was significantly associated with an increased risk of AF. It is uncertain whether maintaining the optimal BP levels can prevent AF in the patients with MS categorized as ‘high-risk’ patients.


Objective: The aim of this study was to evaluate the influence of control of BP on the occurrence of new-onset atrial fibrillation in patients with Metabolic Syndrome.


Methods: Into this observational study, was enrolled 435 consecutive patients (210 males and 225 females) aged 45-79 years who fulfilled criteria for MS. Participants were selected among primary and secondary care patients, who were receiving ongoing care for arterial hypertension in the period from November 2018 till November 2021. The study was conducted at outpatients in 5 Health Care Clinics (3 Secondary Health Care Clinics and 2 Primary Health Clinics). Patient were categorized according to their BP levels as Group 1-patients with controlled BP, {(patients aged < 65 years Systolic Blood Pressure (SBP) of 120 - 130 mmHg, patients aged ≥ 65 years SBP of 130 - 139 mmHg)} and Diastolic Blood Pressure (DBP), {(patients aged < 65 years of < 80 mmHg. but not < 70 mmHg; patients aged ≥ 65 years of 85 - 89 mmHg)}, or Group 2-patients with uncontrolled BP(> 130/80 mmHg),and in patients aged ≥ 65 years BP (≥ 140/90 mmHg ).


Results: New-onset of AF, was more frequent in participants with uncontrolled BP, respectively (34.7% vs. 19.5%, p = 0.009).Patients with uncontrolled BP have more frequent persistent AF (15.2% vs. 0.04%) and permanent AF (0.08% vs. 0.02%), whereas there was not significant changes between groups in relation to frequency of paroxysmal AF, respectively (12.8% vs. 10.9%, p = 0.29). There was observed significant association of uncontrolled BP with: increased frequency of AF (OR = 2.193; 95% CI 1.390 - 3.439), persistent AF (OR = 3.931; 95% CI 1.771 - 8.084), permanent AF (OR = 4.138; 95% CI 1.383-12.381), LA. Dimension ≥ 2.2 cm/m2 (OR = 2.089, 95% CI 1.330 - 3.252), BMI (OR = 5.226, 95% CI 3.155 - 8.659) and 5-risk factors for MS, respectively (OR = 2.998, 95% CI 1.833 - 4.901).


Conclusion: Optimal BP levels, can reduce the frequency of new-onset AF in patients with MS categorized as ‘high-risk’ patients. Uncontrolled BP was associated with an increased risk of both subtypes of AF (persistent and permanent) in the patients with MS categorized as ‘high-risk’ patients.

Article Details

Jani, Y., Haxhirexha, K., Haxhirexha, F., Pocesta, B., Rexhepi, A., Ferati, F., … Zylbeari, L. (2022). Control of arterial hypertension and risk of new-onset of atrial fibrillation in patients with metabolic syndrome. Journal of Cardiology and Cardiovascular Medicine, 7(1), 017–022. https://doi.org/10.29328/journal.jccm.1001126
Research Articles

Copyright (c) 2022 Jani Y, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The Journal of Cardiology and Cardiovascular Medicine is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.

License: Copyright © 2017 - 2025 | Creative Commons License Open Access by Journal of Cardiology and Cardiovascular Medicine is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.

With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.

Compliance 'CC BY' license helps in:

Permission to read and download
Permission to display in a repository
Permission to translate
Commercial uses of manuscript

'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license. 

Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc. 2017; 6: 116. e005155. PubMed: https://pubmed.ncbi.nlm.nih.gov/28455344/

Ford ES. Prevalence of Metabolic Syndrome defined by the international Diabetes Federation among adult in the US. Diabetes Care. 2005; 28: 2745-2749. PubMed: https://pubmed.ncbi.nlm.nih.gov/16249550/

Tanner RM, Baber U, Carson AP, Voeks J, Brown TM, et al. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol. 2011; 108: 227–232. PubMed: https://pubmed.ncbi.nlm.nih.gov/21530935/

Karantzopoulos P, Kokoris S, Papaionnides D. The association of metabolic syndrome with atrial fibrillation:an emerging epidemiological and patophysiologica hypothesis. Cardiology. 2005; 104: 148-149. PubMed: https://pubmed.ncbi.nlm.nih.gov/16118494/

Arthur RM, Carl JL, James DN, James OK, Daniel PM, et al. Cardiometabolic Risk Factors and Atrial Fibrillation. Rev Cardiovasc Med. 2013; 14: 73-81. PubMed: https://pubmed.ncbi.nlm.nih.gov/24448257/

Manolis AJ, Rosel FA, Coca A. Hypertension and Atrial Fibrillation:diagnostic approach,prevention and treatment.Position paper of the Working Group “Hypertension Arrhythmias and Thombosis” of the European Society of Hypertension. J Hypertens. 2012; 30: 239-252.

Georgiopoulos G, Ntritsos G, Stamatelopoulos K, Tsioufis C, Aimo A, et al. The relationship between blood pressure and risk of atrial fibrillation: a Mendelian randomization study. Eur J Prev Cardiol. 2021; zwab005. PubMed: https://pubmed.ncbi.nlm.nih.gov/33556963/

Paolo V, Fabio A, Gianpaolo R. Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies. Circ Res. 2018; 122: 352-368. PubMed: https://pubmed.ncbi.nlm.nih.gov/29348255/

Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): An open-label randomised trial. Lancet. 2009; 374: 525–533. PubMed: https://pubmed.ncbi.nlm.nih.gov/19683638/

Chen LY, Bigger JT, Hickey KT, Chen H, Lopez-Jimenez C, et al. Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. Am J Hypertens. 2016; 29: 1276–1282. PubMed: https://pubmed.ncbi.nlm.nih.gov/26476086/

Ford ES, Li C, Zhao G. Prevelence and correlates of Metabolic Synrome based on a harmonious definition among adults in the US. J Diabetes. 2010; 2: 180-1993. PubMed: https://pubmed.ncbi.nlm.nih.gov/20923483/

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for he Study of Obesity. Circulation. 2009; 120: 1640–1645. PubMed: https://pubmed.ncbi.nlm.nih.gov/19805654/

American Diabetes Association. Standarts for Medical Care for Patients with Diabetes Mellitus. Diabetes Care. 2002; 25: 213-229. PubMed: https://pubmed.ncbi.nlm.nih.gov/12502618/

Williams B, Mancia G, Spiering W, Agabiti E, Azii M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39: 3021–3104. PubMed: https://pubmed.ncbi.nlm.nih.gov/30165516/

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015; 16: 233–271. PubMed: https://pubmed.ncbi.nlm.nih.gov/25559473/

Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29: 277–314. PubMed: https://pubmed.ncbi.nlm.nih.gov/27037982/

de Simone G, Daniel RS, Devereux RB, Meyer RA, Roman MJ, et al. Left ventricular mass and body size in normotensive children and adults:assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20: 1251-1260. PubMed: https://pubmed.ncbi.nlm.nih.gov/1401629/

Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123: 1501–1508. PubMed: https://pubmed.ncbi.nlm.nih.gov/21444879/

Georgiopoulos G, Ntritsos G, Stamatelopoulos K, Tsioufis C, Aimo A, et al. The relationship between blood pressure and risk of atrial fibrillation: a Mendelian randomization study. Eur J Prev Cardiol. 2021. PubMed: https://pubmed.ncbi.nlm.nih.gov/33556963/

Verdecchia PF. Angeli P, Reboldi G. Hypertension and Atrial Fibrillation. Circulat Res. 2018; 122: 352–368. PubMed: https://pubmed.ncbi.nlm.nih.gov/29348255/

Alves-Cabratosa L, García-Gil M, Comas-Cufí M, Ponjoan A, Martí R, et al. Incident atrial fibrillation hazard in hypertensive population: a risk function from and for clinical practice. Hypertension. 2015; 65: 1180-1186. PubMed: https://pubmed.ncbi.nlm.nih.gov/25847950/

Verdecchia P, Mazzotta G, Angeli F, Reboldi G. Above which blood pressure level does the risk of atrial fibrillation increase? Hypertension. 2012; 59:184–185. PubMed: https://pubmed.ncbi.nlm.nih.gov/22252400/

Soliman EZ, Rahman AF, Zhang Z, Rodriguez CJ, Chang TI, et al. Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation. Hypertension. 2020; 75: 1491–1496. PubMed: https://pubmed.ncbi.nlm.nih.gov/32362229/

Chen LY, Bigger JT, Hickey KT, Chen H, Lopez-Jimenez C, et al. Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. Am J Hypertens. 2016; 29: 1276–1282. PubMed: https://pubmed.ncbi.nlm.nih.gov/26476086/

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 138: e484–e594. PubMed: https://pubmed.ncbi.nlm.nih.gov/29133354/

de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, et al. Progression From Paroxysmal to Persistent Atrial Fibrillation. J Am Coll Cardiol. 2010; 55: 725–731. PubMed: https://pubmed.ncbi.nlm.nih.gov/20170808/

Thomas MC, Dublin S, Kaplan RC, Glazer NL, Lumley T, et al. Blood Pressure Control and Risk of Incident Atrial Fibrillation. Am J Hypertens. 2008; 21: 1111–1116. PubMed: https://pubmed.ncbi.nlm.nih.gov/18756257/

Sandhu RK, Conen D, Tedrow UB, Fitzgerald KC, Pradhan AD, et al. Predisposing Factors Associated With Development of Persistent Compared with Paroxysmal Atrial Fibrillation. J Am Heart Assoc. 2014; 3: e000916. PubMed: https://pubmed.ncbi.nlm.nih.gov/24786144/

Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003; 91: 9G-14G. PubMed: https://pubmed.ncbi.nlm.nih.gov/12781903/

Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart study.Hypertension. 1995; 25: 1155–1160. PubMed: https://pubmed.ncbi.nlm.nih.gov/7768556/

Okin PM, Gerdts E, Wachtell K, Oikarinen L, Nieminen MS, et al. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens. 2010; 28: 1534–1540. PubMed: https://pubmed.ncbi.nlm.nih.gov/20589977/

Francesca C, Anna M, Pierdomenico U, Matteo De R, Andrea De L, et al. Ambulatory blood pressure and risk of new-onset atrial fibrillation in treated hypertensive patients. J Clin Hypertens (Greenwich). 2021; 23: 147-152. PubMed: https://pubmed.ncbi.nlm.nih.gov/33242233/

Larsson SC, Back M, Rees J, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. Eur Heart J. 2020; 41: 221–226. PubMed: https://pubmed.ncbi.nlm.nih.gov/31195408/